All In Biotech

Drug Trial Radar · NCT07785193

A Study of Subcutaneous FL115 Monotherapy in Participants With Advanced Solid Tumors

An Open-label, Multicenter, Dose-escalation Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of FL115 Injection Administered Subcutaneously as Monotherapy in Participants With Advanced Solid Tumours

Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

29

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Sep 2027

Study completion Sep 2029

Sponsor

Sponsor type
Industry
Collaborators
Novotech (Australia) Pty Limited
First posted
Aug 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter, dose-escalation Phase Ib clinical study to evaluate the safety, tolerability, efficacy, PK, and PD of FL115 injection administered subcutaneously as monotherapy in participants with advanced solid tumours. All enrolled participants will receive FL115 by subcutaneous injection. Each treatment cycle comprises 21 days, with administration once every 3 weeks (Q3W). Treatment will continue until initiation of new anti-tumour therapy, progressive disease (PD), unacceptable toxicity, death, withdrawal of informed consent, loss to follow-up, or study termination by the Sponsor, whichever occurs first.

Conditions

  • Advanced Solid Tumours

Interventions

  • FL115Drug

    FL115 is a novel long-acting IL-15 agonist designed as a fusion protein with a mutated IL-15 structure (IL-15\[N72D\]/IL-15Rα-sFc).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of TEAEs and SAEsTime frame: TEAEs: From first dose to 30 days after the last dose or initiation of new anti-tumour therapy, whichever occurs first. SAEs: From PICF signing through the TEAE collection period; thereafter, only treatment- or study-related SAEs will be collected.
  2. MTD and RP2DTime frame: through study completion, an average of 15 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Integrated Clinical Oncology Network Pty Ltd

    South Brisbane, Queensland, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.